MannKind Corporation (MNKD)
Stock Price:
$2.05 USD
-0.05 (-2.38%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
After-hours: $2.07 +0.02 (0.98%) Oct 23, 7:58 PM
Key Info
| Market Cap |
469.81M |
| Revenue (ttm) |
61.94M |
| Net Income (ttm) |
-44.21M |
| Shares Out |
229.18M |
| EPS (ttm) |
-0.21 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 23, 2020 |
| Last Price |
$2.05 |
| Previous Close |
$2.10 |
| Change ($) |
-0.05 |
| Change (%) |
-2.38% |
| Day's Open |
2.14 |
| Day's Range |
1.98 - 2.14 |
| Day's Volume |
1,679,210 |
| 52-Week Range |
0.80 - 2.48 |
More Stats
| Market Cap |
469.81M |
| Enterprise Value |
529.86M |
| Earnings Date (est) |
Nov 4, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
229.18M |
| Float |
215.32M |
| EPS (basic) |
-0.21 |
| EPS (diluted) |
-0.21 |
| FCF / Share |
-0.34 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
26.36M |
| Short Ratio |
12.17 |
| Short % of Float |
12.24% |
| Beta |
2.10 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
7.59 |
| PB Ratio |
n/a |
| Revenue |
61.94M |
| Operating Income |
-36.32M |
| Net Income |
-44.21M |
| Free Cash Flow |
-73.43M |
| Net Cash |
-60.05M |
| Net Cash / Share |
-0.26 |
| Gross Margin |
56.60% |
| Operating Margin |
-58.64% |
| Profit Margin |
-71.40% |
| FCF Margin |
-118.56% |
| ROA |
-23.32% |
| ROE |
n/a |
| ROIC |
-29.70% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (5)
| Buy |
5 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$3.00*
(46.34% upside)
Low
2.50
Current: $2.05
High
4.00
Target: 3.00
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 63.04 | 27.86 | 11.75 | 175 | - | - | - | 0.04 | 0.05 | 0.09 |
| Revenue Growth | 126.28% | 137.2% | -93.28% | - | - | - | - | -30% | -46.24% | - |
| Gross Profit | 35.06 | 7.39 | -5.48 | 125 | -64.75 | - | - | 0.04 | 0.05 | 0.09 |
| Operating Income | -46.51 | -81.06 | -94.55 | 63.83 | -342 | -180 | -169 | -147 | -141 | -152 |
| Net Income | -51.90 | -86.98 | -117 | 126 | -368 | -198 | -191 | -169 | -161 | -171 |
| Shares Outstanding | 196 | 144 | 104 | 92.05 | 81.23 | 77.05 | 59.92 | 36.17 | 24.36 | 22.73 |
| Earnings Per Share | -0.27 | -0.60 | -1.13 | 1.36 | -4.54 | -2.57 | -3.20 | -4.70 | -6.60 | -7.50 |
| Operating Cash Flow | -88.48 | -37.73 | -64.78 | -78.09 | -57.23 | 4.09 | -129 | -120 | -124 | -149 |
| Capital Expenditures | -2.57 | -0.23 | 0.02 | -1.13 | -10.20 | -24.10 | -7.99 | -0.56 | -6.77 | -9.54 |
| Free Cash Flow | -91.05 | -37.97 | -64.75 | -79.22 | -67.44 | -20.01 | -137 | -120 | -131 | -158 |
| Cash & Equivalents | 50.20 | 71.68 | 48.36 | 22.90 | 59.07 | 121 | 70.79 | 61.84 | 2.68 | 70.43 |
| Total Debt | 121 | 102 | 157 | 148 | 214 | 225 | 250 | 332 | 488 | 445 |
| Net Cash / Debt | -71.21 | -30.80 | -108 | -126 | -155 | -104 | -179 | -270 | -485 | -374 |
| Assets | 93.73 | 108 | 84.58 | 107 | 126 | 394 | 259 | 251 | 200 | 277 |
| Liabilities | 284 | 283 | 299 | 291 | 477 | 468 | 289 | 362 | 513 | 463 |
| Book Value | -191 | -175 | -215 | -184 | -350 | -73.77 | -30.71 | -111 | -314 | -186 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
MannKind Corporation |
| Country |
United States |
| Employees |
232 |
| CEO |
Michael E. Castagna |
Stock Information
| Ticker Symbol |
MNKD |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: MNKD |
| IPO Date |
July 28, 2004 |
Description
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of treprostinil used for the treatment of pulmonary arterial hypertension. MannKind Corporation was founded in 1991 and is headquartered in Westlake Village, California.